April 29, 2017
Recommended Topic Related To:


"Nov. 17, 2014 -- Voters in Colorado and Oregon rejected measures this month that would have required labels on foods made with genetically modified organisms (GMOs).

Such foods, a high-tech version of breeding that farmers have been"...


Dextrose Injection 5%

How Supplied


Dextrose (hydrous dextrose (hydrous dextrose) ) Injection, USP is indicated as a source of water and calories.


As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.

Additives may be incompatible. Complete information is not available.

Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.


Dextrose (hydrous dextrose (hydrous dextrose) ) Injection, USP in VIAFLEX plastic container is available as follows:

Code Size ( mL) NDC Product Name
2B0080 25 Quad pack 0338-0017-10 5% Dextrose Injection, USP
2B0086 50 Single pack 0338-0017-41  
2B0081   Quad pack 0338-0017-11 5% Dextrose Injection, USP
2B0088   Multi pack 0338-0017-31  
2B0087 100 Single pack 0338-0017-48  
2B0082   Quad pack 0338-0017-18  
2B0089   Multi pack 0338-0017-38  
2B0061 150   0338-0017-01 5% Dextrose Injection, USP
2B0062 250   0338-0017-02  
2B0063 500   0338-0017-03  
2B0064 1000   0338-0017-04  
2B0162 250   0338-0023-02  
2B0163 500   0338-0023-03 10% Dextrose Injection, USP
2B0164 1000   0338-0023-04  

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25deg;C/ 77deg;F); brief exposure up to 40deg;C/ 104deg;F does not adversely affect the product.

Directions For Use Of Viaflex Plastic Container

Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

To Open

Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow “ To Add Medication” directions below.

Preparation for Administration
  1. Suspend container from eyelet support.
  2. Remove plastic protector from outlet port at bottom of container.
  3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Warning: Additives may be incompatible.

To add medication before solution administration
  1. Prepare medication site.
  2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
  3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
To add medication during solution administration
  1. Close clamp on the set.
  2. Prepare medication site.
  3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
  4. Remove container from IV pole and/or turn to an upright position.
  5. Evacuate both ports by squeezing them while container is in the upright position.
  6. Mix solution and medication thoroughly.
  7. Return container to in-use position and continue administration.

Baxter Healthcare Corporation, Deerfield, IL 60015 USA. FDA revision date: n/a

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/10/2008

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Weight Loss Wisdom

Get tips, recipes and inspiration.